Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

entities : Agilent technologies, inc.    source : Www.fda.gov    save search

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Published: 2021-06-11 (Crawled : 18:03) - fda.gov
A | $132.73 0.22% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: 0.21% H: 0.17% C: 0.12%

approval fda fda approval nivolumab
Gainers vs Losers
67% 33%

Top 10 Gainers

Your saved searches
Save your searches and get alerts when important news are released.